UNITED THERAPEUTICS CORP (UTHR) Fundamental Analysis & Valuation

NASDAQ:UTHR • US91307C1027

Current stock price

571.35 USD
+0.28 (+0.05%)
At close:
571.35 USD
0 (0%)
After Hours:

This UTHR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. UTHR Profitability Analysis

1.1 Basic Checks

  • In the past year UTHR was profitable.
  • In the past year UTHR had a positive cash flow from operations.
  • UTHR had positive earnings in each of the past 5 years.
  • In the past 5 years UTHR always reported a positive cash flow from operatings.
UTHR Yearly Net Income VS EBIT VS OCF VS FCFUTHR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

1.2 Ratios

  • With an excellent Return On Assets value of 16.94%, UTHR belongs to the best of the industry, outperforming 95.53% of the companies in the same industry.
  • UTHR has a Return On Equity of 18.81%. This is amongst the best in the industry. UTHR outperforms 94.76% of its industry peers.
  • UTHR has a Return On Invested Capital of 16.10%. This is amongst the best in the industry. UTHR outperforms 95.92% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for UTHR is significantly below the industry average of 28.06%.
  • The last Return On Invested Capital (16.10%) for UTHR is above the 3 year average (15.88%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROIC 16.1%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
UTHR Yearly ROA, ROE, ROICUTHR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • The Profit Margin of UTHR (41.94%) is better than 97.28% of its industry peers.
  • In the last couple of years the Profit Margin of UTHR has grown nicely.
  • With an excellent Operating Margin value of 47.63%, UTHR belongs to the best of the industry, outperforming 99.22% of the companies in the same industry.
  • UTHR's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 87.92%, UTHR belongs to the top of the industry, outperforming 88.93% of the companies in the same industry.
  • UTHR's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
UTHR Yearly Profit, Operating, Gross MarginsUTHR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. UTHR Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so UTHR is still creating some value.
  • The number of shares outstanding for UTHR has been reduced compared to 1 year ago.
  • Compared to 5 years ago, UTHR has less shares outstanding
  • UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
UTHR Yearly Shares OutstandingUTHR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
UTHR Yearly Total Debt VS Total AssetsUTHR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • UTHR has an Altman-Z score of 22.21. This indicates that UTHR is financially healthy and has little risk of bankruptcy at the moment.
  • UTHR has a better Altman-Z score (22.21) than 89.51% of its industry peers.
  • UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 22.21
ROIC/WACC1.69
WACC9.52%
UTHR Yearly LT Debt VS Equity VS FCFUTHR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

  • UTHR has a Current Ratio of 6.60. This indicates that UTHR is financially healthy and has no problem in meeting its short term obligations.
  • UTHR has a Current ratio of 6.60. This is in the better half of the industry: UTHR outperforms 65.24% of its industry peers.
  • A Quick Ratio of 6.28 indicates that UTHR has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 6.28, UTHR is doing good in the industry, outperforming 64.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.6
Quick Ratio 6.28
UTHR Yearly Current Assets VS Current LiabilitesUTHR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. UTHR Growth Analysis

3.1 Past

  • UTHR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.41%, which is quite good.
  • UTHR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 19.23% yearly.
  • UTHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.61%.
  • Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 16.50% on average per year.
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%

3.2 Future

  • UTHR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.14% yearly.
  • UTHR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.18% yearly.
EPS Next Y4.76%
EPS Next 2Y11.22%
EPS Next 3Y12.44%
EPS Next 5Y14.14%
Revenue Next Year3.67%
Revenue Next 2Y8.8%
Revenue Next 3Y11.06%
Revenue Next 5Y14.18%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
UTHR Yearly Revenue VS EstimatesUTHR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
UTHR Yearly EPS VS EstimatesUTHR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30 40 50

More info and screens

Find the best growth stocksShow best growing peers

6

4. UTHR Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 20.48 indicates a rather expensive valuation of UTHR.
  • Compared to the rest of the industry, the Price/Earnings ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 93.20% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.77. UTHR is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 19.55, UTHR is valued on the expensive side.
  • UTHR's Price/Forward Earnings ratio is rather cheap when compared to the industry. UTHR is cheaper than 94.37% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of UTHR to the average of the S&P500 Index (21.75), we can say UTHR is valued inline with the index average.
Industry RankSector Rank
PE 20.48
Fwd PE 19.55
UTHR Price Earnings VS Forward Price EarningsUTHR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, UTHR is valued cheaper than 94.76% of the companies in the same industry.
  • UTHR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. UTHR is cheaper than 94.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF 24.19
EV/EBITDA 12.96
UTHR Per share dataUTHR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates UTHR does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of UTHR may justify a higher PE ratio.
  • A more expensive valuation may be justified as UTHR's earnings are expected to grow with 12.44% in the coming years.
PEG (NY)4.31
PEG (5Y)1.07
EPS Next 2Y11.22%
EPS Next 3Y12.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UTHR Dividend Analysis

5.1 Amount

  • UTHR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UTHR Fundamentals: All Metrics, Ratios and Statistics

UNITED THERAPEUTICS CORP

NASDAQ:UTHR (4/30/2026, 8:21:53 PM)

After market: 571.35 0 (0%)

571.35

+0.28 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners97.31%
Inst Owner Change0.18%
Ins Owners1.94%
Ins Owner Change32.81%
Market Cap25.04B
Revenue(TTM)3.18B
Net Income(TTM)1.33B
Analysts81.9
Price Target627.88 (9.89%)
Short Float %6.31%
Short Ratio4.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.35%
Min EPS beat(2)-2.35%
Max EPS beat(2)5.05%
EPS beat(4)1
Avg EPS beat(4)-1.8%
Min EPS beat(4)-9.46%
Max EPS beat(4)5.05%
EPS beat(8)2
Avg EPS beat(8)-2.1%
EPS beat(12)6
Avg EPS beat(12)0.77%
EPS beat(16)8
Avg EPS beat(16)-0.29%
Revenue beat(2)0
Avg Revenue beat(2)-4.27%
Min Revenue beat(2)-4.72%
Max Revenue beat(2)-3.81%
Revenue beat(4)1
Avg Revenue beat(4)-1.12%
Min Revenue beat(4)-4.72%
Max Revenue beat(4)6.71%
Revenue beat(8)4
Avg Revenue beat(8)0.39%
Revenue beat(12)7
Avg Revenue beat(12)1.48%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)14.83%
PT rev (3m)16.33%
EPS NQ rev (1m)-1.76%
EPS NQ rev (3m)-5.53%
EPS NY rev (1m)-2.15%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)-1.01%
Revenue NQ rev (3m)-2.37%
Revenue NY rev (1m)-0.62%
Revenue NY rev (3m)-2%
Valuation
Industry RankSector Rank
PE 20.48
Fwd PE 19.55
P/S 7.87
P/FCF 24.19
P/OCF 16.04
P/B 3.53
P/tB 3.59
EV/EBITDA 12.96
EPS(TTM)27.9
EY4.88%
EPS(NY)29.23
Fwd EY5.12%
FCF(TTM)23.62
FCFY4.13%
OCF(TTM)35.62
OCFY6.23%
SpS72.61
BVpS161.9
TBVpS159.25
PEG (NY)4.31
PEG (5Y)1.07
Graham Number318.802 (-44.2%)
Profitability
Industry RankSector Rank
ROA 16.94%
ROE 18.81%
ROCE 20.71%
ROIC 16.1%
ROICexc 26.8%
ROICexgc 27.52%
OM 47.63%
PM (TTM) 41.94%
GM 87.92%
FCFM 32.53%
ROA(3y)15.64%
ROA(5y)13.63%
ROE(3y)17.94%
ROE(5y)16.2%
ROIC(3y)15.88%
ROIC(5y)14.43%
ROICexc(3y)29.26%
ROICexc(5y)26.59%
ROICexgc(3y)30.21%
ROICexgc(5y)27.3%
ROCE(3y)20.42%
ROCE(5y)18.56%
ROICexgc growth 3Y0.25%
ROICexgc growth 5Y6.53%
ROICexc growth 3Y-0.12%
ROICexc growth 5Y7.38%
OM growth 3Y-2.34%
OM growth 5Y3.56%
PM growth 3Y3.74%
PM growth 5Y3.86%
GM growth 3Y-1.56%
GM growth 5Y-1.06%
F-Score8
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 614.49%
Cap/Sales 16.53%
Interest Coverage 112.28
Cash Conversion 97.49%
Profit Quality 77.56%
Current Ratio 6.6
Quick Ratio 6.28
Altman-Z 22.21
F-Score8
WACC9.52%
ROIC/WACC1.69
Cap/Depr(3y)462.52%
Cap/Depr(5y)380.04%
Cap/Sales(3y)11.66%
Cap/Sales(5y)9.87%
Profit Quality(3y)81.3%
Profit Quality(5y)87.1%
High Growth Momentum
Growth
EPS 1Y (TTM)13.41%
EPS 3Y22.93%
EPS 5Y19.23%
EPS Q2Q%24.39%
EPS Next Y4.76%
EPS Next 2Y11.22%
EPS Next 3Y12.44%
EPS Next 5Y14.14%
Revenue 1Y (TTM)10.61%
Revenue growth 3Y18.02%
Revenue growth 5Y16.5%
Sales Q2Q%7.38%
Revenue Next Year3.67%
Revenue Next 2Y8.8%
Revenue Next 3Y11.06%
Revenue Next 5Y14.18%
EBIT growth 1Y4.68%
EBIT growth 3Y15.26%
EBIT growth 5Y20.65%
EBIT Next Year9.4%
EBIT Next 3Y14.92%
EBIT Next 5Y-7.27%
FCF growth 1Y-4.2%
FCF growth 3Y15.97%
FCF growth 5Y8.25%
OCF growth 1Y17.64%
OCF growth 3Y24.84%
OCF growth 5Y15.62%

UNITED THERAPEUTICS CORP / UTHR Fundamental Analysis FAQ

What is the fundamental rating for UTHR stock?

ChartMill assigns a fundamental rating of 7 / 10 to UTHR.


What is the valuation status of UNITED THERAPEUTICS CORP (UTHR) stock?

ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.


How profitable is UNITED THERAPEUTICS CORP (UTHR) stock?

UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.


Can you provide the PE and PB ratios for UTHR stock?

The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 20.48 and the Price/Book (PB) ratio is 3.53.